Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 345

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 345
---
 to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. Holders of “2016” preferred shares” are entitled to vote at our shareholders’ meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares.

In April 3, 2021, the retention period for the "2017 free preferred shares" has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. According to these same performance criteria, the Executive Board of April 7, 2021 noted that the "2017 preferred shares" did not give right to any ordinary shares. The “2017 preferred shares” will not be redeemed by the Company and will remain incorporated into the capital, unless subsequently decided by the Executive Board. As the conversion is void, the "2017 preferred shares" no longer give the right to vote at our general meetings, nor to receive dividends.

The table below presents the historical changes in the share capital of the Company as of December 31, 2022, 2023 and 2024, respectively:

F-49

                                                                                                                                                                                 Number of                                         
  Date                   Nature of the Transactions                                                                                          Share premium                       Common shares                      Nominal value  
                         January 1, 2022                                                                                      3,977,836                         375,219,667                         79,542,627      € 0.05         
  February 14, 2022      Capital increase by issuance of common shares (exercise of share warrants)                                                                   1,493      750                                € 0.05         
  February 14, 2022      Capital increase by issuance of common shares                                                            2,316                             187,596                             46,320      € 0.05         
  February 14, 2022      Capital increase by issuance of common shares (definitive acquisition of free shares )                   6,948           ( 6,948)                                             138,960      € 0.05         
  April 22, 2022         Capital increase by issuance of common shares (definitive acquisition of free shares )                   1,250           ( 1,250)                                              25,000      € 0.05         
  July 13, 2022          Capital increase by issuance of common shares (definitive